Skip to main content
SpringerLink
Log in

Siagoside

GM1, Sygen®

  • Section 1: Neuroprotection in Stroke
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bianchetti A, Guillou GB, Khin-Maung-Gyi F, et al. Pharmacokinetics of Sygen (Rm) after single IV administration to healthy volunteers. J Clin Pharmacol 1993 Oct; 33: 997

    Google Scholar 

  2. Schneider JS, Roeltgen DP, Mancall EL, et al. Parkinson’s disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology 1998 Jul; 50: 1630–6

    Article  PubMed  CAS  Google Scholar 

  3. Lenzi GL, Grigoletto F, Gent M, et al. Early treatment of stroke with monosialoganglioside GM-1: efficacy and safety results of the Early Stroke Trial. Stroke 1994 Aug; 25: 1552–8

    Article  PubMed  CAS  Google Scholar 

  4. Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury: a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991 Jan 27; 324: 1829–38

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siagoside. Drugs R&D 1, 36–37 (1999). https://doi.org/10.2165/00126839-199901010-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901010-00014

Keywords

Search

Navigation